AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5
slide-6

Sitabend-M Tablet

Prescription Icon
Prescription Required

Marketer

Bal Pharma Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitabend-M Tablet

Diabetam-Duo tablets combine two medications to effectively manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps mitigate serious diabetic complications like nephropathy and retinopathy, potentially lowering the risk of cardiovascular events. Diabetam-Duo may be prescribed independently or in conjunction with other antidiabetic therapies. Optimal results are achieved with a balanced diet and consistent physical activity. Dosage is individualized based on your health status, glycemic control, and other medications. Consuming the tablets with food minimizes gastrointestinal discomfort. For maximum effectiveness, adhere to a consistent daily dosing schedule; discontinue use only under your physician's guidance. Continued adherence to the prescribed diet and exercise regimen is crucial for successful diabetes management, as lifestyle significantly impacts glycemic control. Common side effects include diarrhea, nausea, vomiting, dyspepsia, cephalalgia, and pharyngitis. Hypoglycemia is a potential adverse effect, especially when used concurrently with insulin or sulfonylureas; learn how to identify and address this. This medication is not universally suitable. Prior to initiating treatment, inform your doctor of any pre-existing renal, hepatic, or cardiac conditions, pancreatic issues, or significant alcohol consumption. Pregnant or lactating individuals should seek medical advice before use. Other medications can interact with Diabetam-Duo; ensure your physician has a complete list of your medications for safety. Alcohol should be limited due to its hypoglycemic effects. Your doctor will monitor renal function and blood glucose levels throughout the treatment course.

Primary Ingredients of Sitabend-M Tablet

The information is unavailable.

Uses of Sitabend-M Tablet

Managing Type 2 Diabetes

Major Benefits of Sitabend-M Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Sitabend-M Tablet with a meal.

Common Side effects of Sitabend-M Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitabend-M Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Sitabend-M Tablet with a meal.

How Sitabend-M Tablet works:

Sitagliptin and metformin, the components of Sitabend-M Tablet, work synergistically to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and increases insulin sensitivity. This combined action results in superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside Sitabend-M Tablet is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitabend-M Tablet during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sitabend-M tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Impaired driving is a possibility if your blood glucose level is either abnormally low or elevated. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitabend-M tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates Sitabend-M tablet use. Physician consultation is recommended. Regular kidney function monitoring is advised during treatment.

LiverLiverUNSAFE

Use of Sitabend-M Tablets is contraindicated in individuals with hepatic impairment; medical advice is recommended before use.

What if you forget to take Sitabend-M Tablet :

Should you forget a Sitabend-M Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitabend-M Tablet

LabelValue
Potential for Dependence None.
Type of Medication Medication for diabetes

FAQs on Sitabend-M Tablet

Sitagliptin and Metformin, combined as Sitabend-M Tablets, treat type 2 diabetes mellitus in adults. This medication enhances blood sugar control when used with a balanced diet and regular physical activity. Metformin reduces liver glucose production and improves insulin responsiveness. Sitagliptin works by suppressing DPP4 enzyme activity, thereby boosting pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Prolonged Sitabend-M Tablet use can indeed lead to Vitamin B12 deficiency by hindering its gastrointestinal absorption. This deficiency, if left unaddressed, may manifest as anemia and neurological complications, including paresthesia in the extremities, generalized weakness, urinary dysfunction, cognitive changes, and ataxia. Therefore, supplemental Vitamin B12 intake, at least annually, is recommended by some experts to mitigate these risks.
Sitabend-M Tablet may cause common side effects including low blood sugar (hypoglycemia), taste changes, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but serious adverse reactions such as lactic acidosis are also possible. Prolonged use may result in vitamin B12 deficiency.
Individuals with hypersensitivity to any Sitabend-M Tablet constituent should not use this medication. Its administration is contraindicated in patients experiencing severe renal dysfunction, hepatic impairment, congestive cardiac failure, lactic acidosis, or diabetic ketoacidosis.
Consuming alcohol concurrently with Sitabend-M Tablet is unsafe and may heighten the risk of developing lactic acidosis.
Maintain this medication within its original, sealed container. Follow the storage guidelines provided on the packaging. Discard any remaining medication. Prevent access by children, pets, and others.
Sitagliptin/metformin combination tablets can cause lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed metformin-associated lactic acidosis (MALA), this rare adverse reaction necessitates caution in patients with kidney impairment, advanced age, or significant alcohol consumption. Symptoms may involve muscle aches or weakness, vertigo, fatigue, cold extremities, dyspnea, nausea, emesis, abdominal discomfort, or bradycardia. Should these symptoms arise, discontinue Sitagliptin/metformin immediately and seek urgent medical attention.
Sitagliptin and Metformin, combined as Sitabend-M Tablets, treat type 2 diabetes mellitus in adults. This medication enhances blood glucose control when used with a suitable diet and regular physical activity. Metformin reduces hepatic glucose production and improves insulin responsiveness. Sitagliptin's action involves DPP4 enzyme inhibition, boosting pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Sitabend-M Tablet may cause common side effects including low blood sugar (hypoglycemia), taste disturbances, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but serious adverse reactions such as lactic acidosis are also possible. Prolonged use may result in vitamin B12 deficiency.
Patients with hypersensitivity to Sitabend-M Tablet ingredients or inactive substances should not use this medication. Its use is contraindicated in individuals with severe renal or hepatic dysfunction, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitabend-M Tablet and alcohol is unsafe due to a heightened risk of lactic acidosis.
Sitagliptin/metformin tablets can cause lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed metformin-associated lactic acidosis (MALA), this rare adverse effect necessitates caution in patients with kidney impairment, the elderly, or those who consume significant alcohol. Symptoms may involve muscle aches or weakness, lightheadedness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, or bradycardia. Should these symptoms arise, discontinue Sitagliptin/metformin immediately and seek urgent medical attention.
Prolonged Sitabend-M Tablet use can lead to Vitamin B12 deficiency by hindering its absorption in the gastrointestinal tract. This deficiency, if left unaddressed, may result in anemia and neurological complications, manifesting as paresthesia in the extremities, generalized weakness, urinary dysfunction, cognitive changes, and ataxia. Preventive measures proposed by some studies include annual supplemental Vitamin B12 intake.
Store the medication in its original, tightly sealed container or packaging, following the storage instructions provided on the label. Discard any leftover medication. Prevent access by children, pets, and others.
Sitagliptin and Metformin, combined as Sitabend-M Tablet, treat type 2 diabetes mellitus in adults. This medication enhances blood sugar control when used alongside a healthy diet and regular physical activity. Metformin reduces glucose production by the liver and improves insulin responsiveness. Sitagliptin's action involves DPP4 enzyme inhibition, boosting insulin secretion from the pancreas. This formulation is unsuitable for individuals under 18.
Sitabend-M Tablet may cause common side effects including low blood sugar (hypoglycemia), taste changes, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis are also possible. Prolonged use may result in vitamin B12 deficiency.
Individuals with hypersensitivity to any Sitabend-M Tablet constituent should not use this medication. Its administration is contraindicated in patients experiencing severe renal or hepatic dysfunction, congestive cardiac failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitabend-M Tablet and alcohol is unsafe due to a heightened risk of lactic acidosis.
Sitagliptin/Metformin tablets can cause lactic acidosis, a serious medical condition resulting from excessive blood lactic acid. This is also termed Metformin-associated lactic acidosis (MALA). While infrequent, this adverse reaction necessitates caution in patients with kidney impairment, the elderly, or those who consume significant alcohol. Symptoms such as muscle aches or weakness, lightheadedness, fatigue, cold extremities, respiratory distress, vomiting, abdominal pain, or bradycardia warrant immediate discontinuation of Sitagliptin/Metformin and prompt medical attention.
Prolonged Sitabend-M Tablet use can indeed lead to Vitamin B12 deficiency. This occurs due to the medication's interference with Vitamin B12 absorption in the gastrointestinal tract. Untreated deficiency may result in anemia and neurological complications, manifesting as numbness and tingling in the extremities, muscle weakness, urinary dysfunction, cognitive changes, and impaired coordination. To mitigate these risks, supplemental Vitamin B12 intake is recommended annually by some experts.
Maintain this medication within its original, sealed container. Store as directed on the packaging. Discard any remaining medication. Prevent access by children, pets, and others.
Sitabend-M Tablet
86
MRP 100
14% off